Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2011 Oct;13(10):1118-24. doi: 10.1093/neuonc/nor110. Epub 2011 Aug 2.

2.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA.

Neuro Oncol. 2007 Jan;9(1):29-38. Epub 2006 Nov 15.

3.

Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.

Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK.

Neurosurgery. 2012 Feb;70(2):361-70. doi: 10.1227/NEU.0b013e3182314f9d.

PMID:
21841523
4.

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, van den Bent MJ.

Eur J Cancer. 2012 May;48(8):1176-84. doi: 10.1016/j.ejca.2012.02.004. Epub 2012 Mar 28.

PMID:
22464345
5.

Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.

Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lütolf UM, Knuth A, Yonekawa Y, Barath K, Broggini-Tenzer A, Pruschy M, Hofer S.

Oncology. 2012;83(1):1-9. doi: 10.1159/000339152. Epub 2012 Jun 8.

PMID:
22688083
6.

Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.

Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS.

Neurosurgery. 1994 Sep;35(3):378-88; discussion 388.

PMID:
7800129
7.

Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.

Nava F, Tramacere I, Fittipaldo A, Bruzzone MG, Dimeco F, Fariselli L, Finocchiaro G, Pollo B, Salmaggi A, Silvani A, Farinotti M, Filippini G.

Neuro Oncol. 2014 May;16(5):719-27. doi: 10.1093/neuonc/not316. Epub 2014 Jan 23.

8.

Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.

McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Bernstein M, Chung C, Millar BA, Laperriere N, Mason WP.

J Neurooncol. 2014 Mar;117(1):147-52. doi: 10.1007/s11060-014-1366-9. Epub 2014 Jan 28.

PMID:
24469854
9.

Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG; Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta.

Neuro Oncol. 2008 Feb;10(1):79-87. Epub 2007 Nov 9.

10.

Benefit of tumor resection for recurrent glioblastoma.

Quick J, Gessler F, Dützmann S, Hattingen E, Harter PN, Weise LM, Franz K, Seifert V, Senft C.

J Neurooncol. 2014 Apr;117(2):365-72. doi: 10.1007/s11060-014-1397-2. Epub 2014 Feb 15.

PMID:
24535317
11.

Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.

Conti A, Pontoriero A, Arpa D, Siragusa C, Tomasello C, Romanelli P, Cardali S, Granata F, De Renzis C, Tomasello F.

Acta Neurochir (Wien). 2012 Feb;154(2):203-9. doi: 10.1007/s00701-011-1184-1. Epub 2011 Oct 9.

PMID:
21984132
12.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC; German Glioma Network.

Ann Oncol. 2013 Dec;24(12):3117-23. doi: 10.1093/annonc/mdt388. Epub 2013 Oct 14.

13.

Efficacy of Surgery and Further Treatment of Progressive Glioblastoma.

Woernle CM, Péus D, Hofer S, Rushing EJ, Held U, Bozinov O, Krayenbühl N, Weller M, Regli L.

World Neurosurg. 2015 Aug;84(2):301-7. doi: 10.1016/j.wneu.2015.03.018. Epub 2015 Mar 19.

PMID:
25797075
14.

Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?

Caroli M, Locatelli M, Campanella R, Motta F, Mora A, Prada F, Borsa S, Martinelli-Boneschi F, Saladino A, Gaini SM.

J Neurooncol. 2007 Aug;84(1):71-7. Epub 2007 Mar 15.

PMID:
17361334
15.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

16.

Is reoperation for recurrence of glioblastoma justified?

Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci AC, Bret P.

Oncol Rep. 2000 Jul-Aug;7(4):899-904.

PMID:
10854567
17.

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS.

Neuro Oncol. 2010 May;12(5):508-16. doi: 10.1093/neuonc/nop063. Epub 2010 Feb 5.

18.

The effect of re-operation on survival in patients with recurrent glioblastoma.

Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A, Pozzati E, Galzio R, Talacchi A, Volpin L, Morandi L, Danieli D, Ermani M, Brandes AA.

Anticancer Res. 2015 Mar;35(3):1743-8.

PMID:
25750337
19.

Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework.

Sughrue ME, Sheean T, Bonney PA, Maurer AJ, Teo C.

Neurosurg Focus. 2015 Mar;38(3):E11. doi: 10.3171/2014.12.FOCUS14726. Review.

PMID:
25727220
20.

Surgery, a prognostic marker for progression-free survival?

Chamberlain MC, Silbergeld DL.

Neuro Oncol. 2012 Apr;14(4):390-1; author reply 391. doi: 10.1093/neuonc/nos057. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk